Following the KEYNOTE-689 presentation in 2025, neoadjuvant immunotherapy has become an integral component of perioperative treatment for head and neck squamous cell carcinoma (HNSCC). As pathologic response is increasingly used to assess treatment efficacy, we evaluated rates of pathologic complete response (pCR...
A. Rustad, T. Omer, Morgan C. Byrd et al.· Cancer Epidemiology, Biomark...· 0 citations
Suicide rates among U.S. patients with cancer are approximately twice those of the general population, with patients with head and neck squamous cell carcinoma (HNSCC) experiencing among the highest risks. Meanwhile, the burden of early-onset (EO) cancers continues to increase, and adolescents and young adults (A...
Kwabena D. Boateng, Sena A. Gbeku, Morgan C. Byrd et al.· Cancer Epidemiology, Biomark...· 0 citations
The findings demonstrate that despite overall improvements in survival, compared to NHW, NHB patients experienced persistent disparities while Hispanics faced a widening disparity in HNC outcomes over time, and highlight the need for culturally tailored, evidence-based interventions to improve early detection and ensur...
Kwabena D. Boateng, Sena A. Gbeku, Gwendolyn de-Graft Johnson et al.· Cancer Epidemiology, Biomark...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.